Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alembic Setting Up For US Oncology Play

Executive Summary

Alembic Pharmaceuticals, which has seen a dazzling FY16, appears set to build on its strong showing in the US with plans for filings in the oncology and dermatology space and a potential ramp up of its own label products there.

You may also be interested in...



Alembic Gears For Derma Push With New JV

Shares of Alembic Pharmaceuticals spurted on Indian bourses on April 21 after the firm said that it had formed a joint venture with the privately held Orbicular Pharmaceutical Technologies and one of its founders, Dr MS Mohan, for dermatology products.

Ex-Sandoz Official To Lead Alembic's US Front End

India's Alembic Pharmaceuticals has put in place its core leadership team in the US, which includes two ex-Sandoz officials, as it moves towards setting up its own front-end there.

Alembic rides generic Abilify wave amid compliance wins

Shares of Alembic Pharmaceuticals surged on Indian bourses, after the US FDA cleared the first set of generic versions of Otsuka's schizophrenia and bipolar disorder drug Abilify (aripiprazole).

Topics

UsernamePublicRestriction

Register

OM011995

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel